These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Histomorphometric correlates of renal failure in IgA nephropathy. Vleming LJ; de Fijter JW; Westendorp RG; Daha MR; Bruijn JA; van Es LA Clin Nephrol; 1998 Jun; 49(6):337-44. PubMed ID: 9696428 [TBL] [Abstract][Full Text] [Related]
27. [Segmental renal hypoplasia: small kidney and malignant arterial hypertension]. Mota Hernández F; Alcalá Carbajal O; Scovino Gudiño R; Velásquez Jones L; Gordillo Paniagua G Bol Med Hosp Infant Mex; 1976; 33(4):763-75. PubMed ID: 952656 [No Abstract] [Full Text] [Related]
28. The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. van den Born BJ; Koopmans RP; van Montfrans GA Am J Hypertens; 2007 Aug; 20(8):900-6. PubMed ID: 17679041 [TBL] [Abstract][Full Text] [Related]
29. Early identification of kidney disease by eGFR: what is the prevalence of eGFR in the population? Cirillo M; Lombardi C; Chiricone D; Bilancio G; Marcarelli F; De Santo NG J Nephrol; 2008; 21 Suppl 13():S102-6. PubMed ID: 18446741 [TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of adult patients with minimal urinary abnormalities and normal renal function. Shu KH; Ho WL; Lu YS; Cheng CH; Wu MJ; Lian JD Clin Nephrol; 1999 Jul; 52(1):5-9. PubMed ID: 10442489 [TBL] [Abstract][Full Text] [Related]
31. [Malignant arterial hypertension and chronic renal insufficiency: anatomoclinical correlations]. Ianhez LE; Saldanha LB; Sabbaga E Rev Hosp Clin Fac Med Sao Paulo; 1978 Aug; 33(4):180-3. PubMed ID: 725418 [No Abstract] [Full Text] [Related]
32. A clinical predictor index for renal survival. Araújo NC; Rioja Lda S; Rebelo MA J Bras Nefrol; 2010 Mar; 32(1):27-32. PubMed ID: 21448516 [TBL] [Abstract][Full Text] [Related]
33. [Clinical laboratory analysis of the course of malignant symptomatic arterial hypertension]. Abugova SP; Arabidze GG; Kukharchuk VV; Kutsenko AI; Paleeva FM Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1982; 5(1):54-7. PubMed ID: 7093047 [TBL] [Abstract][Full Text] [Related]
34. Focal segmental glomerulosclerosis in malignant hypertension. Kadiri S; Thomas JO S Afr Med J; 2002 Apr; 92(4):303-5. PubMed ID: 12056363 [TBL] [Abstract][Full Text] [Related]
35. Malignant hypertension: a rare problem or is it underdiagnosed? Shantsila A; Shantsila E; Lip GY Curr Vasc Pharmacol; 2010 Nov; 8(6):775-9. PubMed ID: 20626341 [TBL] [Abstract][Full Text] [Related]
37. Lack of difference between malignant and accelerated hypertension. Ahmed ME; Walker JM; Beevers DG; Beevers M Br Med J (Clin Res Ed); 1986 Jan; 292(6515):235-7. PubMed ID: 3081084 [TBL] [Abstract][Full Text] [Related]
38. Renal proliferative arteriopathies and associated glomerular changes: a light and electron microscopic study. Sinclair RA; Antonovych TT; Mostofi FK Hum Pathol; 1976 Sep; 7(5):565-88. PubMed ID: 987010 [TBL] [Abstract][Full Text] [Related]
39. [Endocrine structures of the kidney in hypertension]. Tsibel' BN; Khodasevich LS Arkh Patol; 1984; 46(9):62-8. PubMed ID: 6508576 [TBL] [Abstract][Full Text] [Related]
40. [Anatomoclinical aspects of malignant hypertension]. Horváth E; Szivós J; Izsák M; Siara E; Tuka P Med Interna (Bucur); 1965 Aug; 17(8):951-8. PubMed ID: 5865248 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]